GLP-2: What do we know? What are we going to discover?

Regulatory Peptides

Volumn 194-195, Issue , 2014, Pages 6-10

  Baldassano, Sara ^a   Amato, Antonella ^a  

^a Dipartimento di Scienze e Tecnologie Molecolari e Biomolecolari   (Italy)

Author keywords

GLP 2; GLP 2 receptor; The enteric nervous system; The gastrointestinal tract

Indexed keywords

GLUCAGON LIKE PEPTIDE 2; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; GLUCAGON LIKE PEPTIDE 2 RECEPTOR AGONIST; GLUCOSE; GUANINE NUCLEOTIDE BINDING PROTEIN; INSULIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TEDUGLUTIDE; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CELLULAR DISTRIBUTION; CROHN DISEASE; DRUG APPROVAL; DRUG IDENTIFICATION; DRUG RESEARCH; DRUG TOLERABILITY; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; IN VITRO STUDY; INFLAMMATION; INSULIN SENSITIVITY; INTESTINE INJURY; INTESTINE INNERVATION; INTRACELLULAR SIGNALING; NERVE CELL GROWTH; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; SHORT BOWEL SYNDROME; ANIMAL; GASTROINTESTINAL TRACT; METABOLISM; SIGNAL TRANSDUCTION;

ANIMALS; ENTERIC NERVOUS SYSTEM; GASTROINTESTINAL TRACT; GLUCAGON-LIKE PEPTIDE 2; HUMANS; INFLAMMATION; SIGNAL TRANSDUCTION;

EID: 84920172976     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2014.09.002     Document Type: Review

References (69)

1. Dockray G.J. Gastrointestinal hormones. Physiology of the gastrointestinal tract 2006, 91-120. Raven, New York. L.R. Johnson, K.E. Barret, F.K. Gishan, J.L. Merchant, H.M. Said, J.D. Wood (Eds.).
2. Holst J.J. Gut glucagon, enteroglucagon, gut glucagon-like immunoreactivity, glicentin current status. Gastroenterology 1983, 84:1602-1613.
3. Holst J.J. Enteroglucagon. Annu Rev Physiol 1997, 59:257-271.
4. Holst J.J. Glucagon-like peptide-1 [GLP-1] a newly discovered GI hormone. Gastroenterology 1994, 107:1848-1855.
5. Baldassano S., Wang G.D., Mulè F., Wood J.D. Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver Physiol 2012, 302:G352-G358.
6. Rotondo A., Amato A., Lentini L., Baldassano S., Mulè F. Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice. Peptides 2011, 32:60-64.
7. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellstrom P.M. Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat. Dig Dis Sci 1998, 43:2284-2290.
8. Amato A., Baldassano S., Liotta R., Serio R., Mule F. Exogenous glucagon-like peptide-1 reduces contractions in human colon circular muscle. J Endocrinol 2014, 221:29-37.
9. Wettergren A., Wojdemann M., Holst J.J. Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 1998, 275:G984-G992.
10. Tolessa T., Gutniak M., Holst J.J., Efendic S., Hellstrom P.M. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. J Clin Invest 1998, 102:764-774.
11. Pocai A. Unraveling oxyntomodulin, GLP1's enigmatic brother. J Endocrinol 2012, 215:335-346.
12. Estall J.L., Drucker D.J. Glucagon-like peptide-2. Annu Rev Nutr 2006, 26:391-411.
13. Jeppesen P.B. Teduglutide for the treatment of short bowel syndrome. Drugs Today 2013, 49:599-614.
14. Shi X., Zhou F., Li X., Chang B., Li D., Wang Y., et al. Central GLP-2 enhances hepatic insulin sensitivity via activating PI3K signaling in POMC neurons. Cell Metab 2013, 18:86-98.
15. Bahrami J., Longuet C., Baggio L.L., Li K., Drucker D.J. Glucagon-like peptide-2 receptor modulates islet adaptation to metabolic stress in the ob/ob mouse. Gastroenterology 2010, 139:857-868.
16. Dubé P.E., Brubaker P.L. Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators. Am J Physiol Endocrinol Metab 2007, 293:E460-E465.
17. Walsh N.A., Yusta B., DaCambra M.P., Anini Y., Drucker D.J., Brubaker P.L. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology 2003, 144:4385-4392.
18. Koehler J.A., Yusta B., Drucker D.J. The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways. Mol Endocrinol 2005, 19:459-473.
19. Leen J.L., Izzo A., Upadhyay C., Rowland K.J., Dube P.E., Gu S., et al. Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts. Endocrinology 2011, 152:436-446.
20. Shi X., Li X., Wang Y., Zhang K., Zhou F., Chan L., et al. Glucagon-like peptide-2-stimulated protein synthesis through the PI 3-kinase-dependent Akt-mTOR signaling pathway. Am J Physiol Endocrinol Metab 2011, 300:E554-E563.
21. Baldassano S., Liu S., Qu M.H., Mulè F., Wood J.D. Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. Am J Physiol Gastrointest Liver Physiol 2009, 297:G800-G805.
22. Cinci L., Faussone-Pellegrini M.S., Rotondo A., Mulè F., Vannucchi M.G. GLP-2 receptor expression in excitatory and inhibitory enteric neurons and its role in mouse duodenum contractility. Neurogastroenterol Motil 2011, 23:e383-e392.
23. Bjerknes M., Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci U S A 2001, 98:12497-12502.
24. Guan X., Karpen H.E., Stephens J., Bukowski J.T., Niu S., Zhang G., et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006, 130:150-164.
25. McDonagh S.C., Lee J., Izzo A., Brubaker P.L. Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine. Am J Physiol Gastrointest Liver Physiol 2007, 293:G461-G468.
26. El-Jamal N., Erdual E., Neunlist M., Koriche D., Dubuquoy C., Maggiotto F., et al. Glugacon-like peptide-2: broad receptor expression, limited therapeutic effect on intestinal inflammation and novel role in liver regeneration. Am J Physiol Gastrointest Liver Physiol 2014, 307:G274-G285.
27. Amato A., Baldassano S., Serio R., Mulè F. Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release. Am J Physiol Gastrointest Liver Physiol 2009, 296:G678-G684.
28. Amato A., Rotondo A., Cinci L., Baldassano S., Vannucchi M.G., Mulè F. Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon. Am J Physiol Gastrointest Liver Physiol 2010, 299:G1038-G1044.
29. Baldassano S., Bellanca A.L., Serio R., Mulè F. Food intake in lean and obese mice after peripheral administration of glucagon-like peptide 2. J Endocrinol 2012, 213:277-284.
30. Tang-Christensen M., Larsen P.J., Thulesen J., Rømer J., Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000, 6:802-807.
31. Nelson D.W., Sharp J.W., Brownfield M.S., Raybould H.E., Ney D.M. Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 2007, 148:1954-1962.
32. Bucinskaite V., Tolessa T., Pedersen J., Rydqvist B., Zerihun L., Holst J.J., et al. Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat. Neurogastroenterol Motil 2009, 21:978-e78.
33. Wøjdemann M., Wettergren A., Hartmann B., Holst J.J. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998, 33:828-832.
34. Nagell C.F., Wettergren A., Pedersen J.F., Mortensen D., Holst J.J. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004, 39:353-358.
35. Whitcomb D.C., Taylor I.L., Vigna S.R. Characterization of saturable binding sites for circulating pancreatic polypeptide in rat brain. Am J Physiol 1990, 259:G687-G691.
36. Wang Y., Guan X. GLP-2 potentiates L-type Ca2+ channel activity associated with stimulated glucose uptake in hippocampal neurons. Am J Physiol Endocrinol Metab 2010, 298:E156-E166.
37. Guan X., Shi X., Li X., Chang B., Wang Y., Li D., et al. GLP-2 receptor in POMC neurons suppresses feeding behavior and gastric motility. Am J Physiol Endocrinol Metab 2012, 303:E853-E864.
38. Baldassano S., Amato A., Cappello F., Rappa F., Mulè F. Glucagon-like peptide-2 and mouse intestinal adaptation to a high-fat diet. J Endocrinol 2013, 217:11-20.
39. Rotondo A., Amato A., Baldassano S., Lentini L., Mulè F. Gastric relaxation induced by glucagon-like peptide-2 in mice fed a high-fat diet or fasted. Peptides 2011, 32:1587-1592.
40. Wøjdemann M., Wettergren A., Hartmann B., Hilsted L., Holst J.J. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999, 84:2513-2517.
41. Meier J.J., Nauck M.A., Pott A., Heinze K., Goetze O., Bulut K., et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006, 130:44-54.
42. Sigalet D.L., Wallace L., De Heuval E., Sharkey K.A. The effects of glucagon-like peptide 2 on enteric neurons in intestinal inflammation. Neurogastroenterol Motil 2010, 22:1318-e350.
43. Sigalet D.L., Wallace L.E., Holst J.J., Martin G.R., Kaji T., Tanaka H., et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol 2007, 293:G211-G221.
44. Mawe G.M., Strong D.S., Sharkey K.A. Plasticity of enteric nerve functions in the inflamed and postinflamed gut. Neurogastroenterol Motil 2009, 21:481-491.
45. Voss U., Sand E., Hellström P.M., Ekblad E. Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons. BMC Gastroenterol 2012, 1:12-30.
46. de Heuvel E., Wallace L., Sharkey K.A., Sigalet D.L. Glucagon-like peptide 2 induces vasoactive intestinal polypeptide expression in enteric neurons via phophatidylinositol 3-kinase-γ signaling. Am J Physiol Endocrinol Metab 2012, 303:E994-E1005.
47. Rowland K.J., Brubaker P.L. The "cryptic" mechanism of action of glucagonlike peptide-2. Am J Physiol Gastrointest Liver Physiol 2011, 301:G1-G8.
48. Lovshin J., Yusta B., Iliopoulos I., Migirdicyan A., Dableh L., Brubaker P.L., et al. Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine. Endocrinology 2000, 141:4194-4201.
49. Amin H., Holst J.J., Hartmann B., Wallace L., Sigalet D. Functional ontogeny of the proglucagon derived peptide axis in human neonates. Pediatrics 2008, 121:e180-e186.
50. Lovshin J.A., Huang Q., Seaberg R., Brubaker P.L., Drucker D.J. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 2004, 145:3495-3506.
51. Cani P.D., Possemiers S., Van de Wiele T., Guiot Y., Everard A., Rottier O., et al. Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut 2009, 58:1091-1103.
52. Trivedi S., Wiber S.C., El-Zimaity H.M., Brubaker P.L. Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer. Am J Physiol Gastrointest Liver Physiol 2012, 302:G840-G849.
53. Iakoubov R., Lauffer L.M., Trivedi S., Kim Y.I., Brubaker P.L. Carcinogenic effects of exogenous and endogenous glucagon-like peptide-2 in azoxymethane-treated mice. Endocrinology 2009, 150:4033-4043.
54. Tappenden K.A., Edelman J., Joelsson B. Teduglutide enhances structural adaptation of the small intestinal mucosa in patients with short bowel syndrome. J Clin Gastroenterol 2013, 47:602-607.
55. Gideon K. Therapeutic drug monitoring principles in the neonate. Clin Chem 1997, 43(1):222-227.
56. Sigalet D.L., de Heuvel E., Wallace L., Bulloch E., Turner J., Wales P.W., et al. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Pept 2014, 188:70-80.
57. Henriksen D.B., Alexandersen P., Hartmann B., Adrian C.L., Byrjalsen I., Bone H.G., et al. A four-month course of treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. Bone November 2009, 45:833-842.
58. Jeppesen P.B., Hartmann B., Thulesen J., Graff J., Lohmann J., Hansen B.S., et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology March 2001, 120:806-815.
59. Jeppesen P.B., Lund P., Gottschalck I.B., Nielsen H.B., Holst J.J., Mortensen J., et al. Short bowel patients treated for two years with glucagon-like Peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract 2009, 2009:616054.
60. Jeppesen P.B., Lund P., Gottschalck I.B., Nielsen H.B., Holst J.J., Mortensen J., et al. Short bowel patients treated for two years with glucagon-like peptide 2 (GLP-2): compliance, safety, and effects on quality of life. Gastroenterol Res Pract 2009, 2009:425759.
61. Thymann T., Stoll B., Mecklenburg L., Burrin D.G., Vegge A., Qvist N., et al. Acute effects of the glucagon-like peptide 2 analogue, teduglutide, on intestinal adaptation in short bowel syndrome. J Pediatr Gastroenterol Nutr 2014, 58:694-702.
62. Blonski W1., Buchner A.M., Aberra F., Lichtenstein G. Teduglutide in Crohn's disease. Expert Opin Biol Ther 2013, 13:1207-1214.
63. Sigalet D.L., Kravarusic D., Butzner D., Hartmann B., Holst J.J., Meddings J. A pilot study examining the relationship among Crohn disease activity, glucagon-like peptide-2 signalling and intestinal function in pediatric patients. Can J Gastroenterol 2013, 27:587-592.
64. Rocca A.S., Brubaker P.L. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999, 140:1687-1694.
65. Brubaker P.L., Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 2003, 81:1005-1012.
66. Neunlist M., Toumi F., Oreschkova T., Denis M., Leborgne J., Laboisse C.L., et al. Human ENS regulates the intestinal epithelial barrier permeability and a tight junction-associated protein ZO-1 via VIPergic pathways. Am J Physiol Gastrointest Liver Physiol 2003, 285:G1028-G1036.
67. Schneider J., Jehle E.C., Starlinger M.J., Neunlist M., Michel K., Hoppe S., et al. Neurotransmitter coding of enteric neurones in the submucous plexus is changed in non-inflamed rectum of patients with Crohn's disease. Neurogastroenterol Motil 2001, 13:255-264.
68. Bjarnason I., MacPherson A., Hollander D. Intestinal permeability: an overview. Gastroenterology 1995, 108:1566-1581.
69. Dong C.X., Zhao W., Solomon C., Rowland K.J., Ackerley C., Robine S., et al. The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function. Endocrinology 2014, 155:370-379.